Show simple item record

dc.contributor.authorKonstantinopoulos, Panagiotis A.en_US
dc.contributor.authorMatulonis, Ursula A.en_US
dc.date.accessioned2014-03-11T10:17:10Z
dc.date.issued2013en_US
dc.identifier.citationKonstantinopoulos, Panagiotis A., and Ursula A. Matulonis. 2013. “Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer.” Frontiers in Oncology 3 (1): 296. doi:10.3389/fonc.2013.00296. http://dx.doi.org/10.3389/fonc.2013.00296.en
dc.identifier.issn2234-943Xen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879349
dc.description.abstractEpithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies over the last three decades have significantly improved the median survival of EOC patients, the plateau of the survival curve has not changed appreciably. Given that EOC is a genetically and biologically heterogeneous disease, identification of specific molecular abnormalities that can be targeted in each individual ovarian cancer on the basis of predictive biomarkers promises to be an effective strategy to improve outcome in this disease. However, for this promise to materialize, appropriate preclinical experimental platforms that recapitulate the complexity of these neoplasms and reliably predict antitumor activity in the clinic are critically important. In this review, we will present the current status and evolution of preclinical models of EOC, including cell lines, immortalized normal cells, xenograft models, patient-derived xenografts, and animal models, and will discuss their potential for oncology drug development.en
dc.language.isoen_USen
dc.publisherFrontiers Media S.A.en
dc.relation.isversionofdoi:10.3389/fonc.2013.00296en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858677/pdf/en
dash.licenseLAAen_US
dc.subjectReview Articleen
dc.subjectepithelial ovarian canceren
dc.subjecthigh-grade serousen
dc.subjectpreclinical modelsen
dc.subjectpersonalized therapyen
dc.subjectcell linesen
dc.subjectxenograftsen
dc.subjectmouse modelsen
dc.subjectpatient-derived xenograftsen
dc.titleCurrent Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Canceren
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalFrontiers in Oncologyen
dash.depositing.authorKonstantinopoulos, Panagiotis A.en_US
dc.date.available2014-03-11T10:17:10Z
dc.identifier.doi10.3389/fonc.2013.00296*
dash.contributor.affiliatedKonstantinopoulos, Panagiotis
dash.contributor.affiliatedMatulonis, Ursula


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record